Globus Medical Q1 Sales Soar 27% to $759.9M, EPS Up 66.6%
Globus Medical’s Q1 net sales jumped 27.0% year-over-year to $759.9 million, with base business up 13.2% excluding Nevro’s $82.7 million contribution. GAAP net income rose 64.7% to $124.3 million, GAAP EPS climbed 66.6% to $0.90, while non-GAAP EPS improved 64.7% to $1.12.
1. First Quarter Financial Highlights
Globus Medical reported worldwide net sales of $759.9 million for Q1 2026, up 27.0% year-over-year, driving GAAP net income of $124.3 million, a 64.7% increase. GAAP diluted EPS rose 66.6% to $0.90 while non-GAAP diluted EPS climbed 64.7% to $1.12.
2. Regional and Base Business Growth
U.S. net sales grew 25.0% year-over-year, supported by a third straight quarter of double-digit spine growth, while international revenues increased 35.6% (27.8% constant currency). Excluding Nevro, base business sales reached $677.2 million, up 13.2% (11.2% constant currency), driven by market share gains and procedural volume strength in core spine.
3. Nevro Acquisition Contribution
Sales from the Nevro acquisition contributed $82.7 million in the quarter, bolstering overall top-line growth and enabling operating leverage. Integration efforts on systems, processes and metrics have begun delivering synergy realization and margin expansion.
4. Full-Year Guidance Update
The company reaffirmed full-year 2026 revenue guidance of $3.18 billion to $3.22 billion and raised non-GAAP diluted EPS outlook to $4.70–$4.80 from $4.40–$4.50, reflecting confidence in sustained earnings growth and disciplined execution across its product ecosystem.